A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Phase 2 Active not recruiting 88 enrolled Fudan University

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a single-center, open-label, phase 2 study to evaluate the efficacy and safety of target therapy for patients with relapsed/metastastic salivary gland carcinoma based on molecular typing.

Timeline

Start: 2023-07-26
Primary completion: 2026-12-30
Completion: 2026-12-30

Publications

Chen GL, Guo Y, Yang Y, Sang Y, Sun S, Liu X, Zhou X, Sheng CY, He X, Wang J, Shi R, Wang Y, Ji Q, Ji D. A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma. NPJ Precis Oncol. 2026 May 13. doi: 10.1038/s41698-026-01463-5. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Leuprolide	Other / unclassified	—	—
Subject	Rezvilutamide	Small molecule	—	—
Subject	SHR-A1921	Monoclonal antibody	—	—
Subject	Trastuzumab Rezetecan	Monoclonal antibody	—	—

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Summary

Timeline

Publications

Drugs

Indications